



Contact:

David Waldman or Justyna Gudaszevska
Crescendo Communications Europe Sp. z o.o.
Email: mmd@crescendo-ir.com
Tel: + 48 71 79 11 551

Milestone Medical Inc. to Present at 3rd Global Life Sciences Conference in Warsaw

LIVINGSTON, NJ, March 12, 2015 – Milestone Medical Inc. (WARSAW: MMD), today announced that Leonard Osser, Chief Executive Officer will present at the upcoming 3rd Global Life Sciences Conference in Warsaw on Thursday June 11th, 2015 at the trading floor of the Warsaw Stock Exchange, Warsaw, Poland. The event brings together executives from leading global companies within the life sciences sector with European institutional investors. A recording of the company's presentation will be posted on Milestone Medical's website following the conference: www.medicalmilestone.com.

Warsaw, the financial capital of Central and Eastern Europe, is a major center of life sciences investment. On June 11th, at the Global Life Sciences Conference, over 100 leading life sciences institutional investors, fund managers and analysts from Central and Eastern Europe will gather in Warsaw to discuss and assess new investment opportunities. They will have access there to Milestone Medical's management through a corporate presentation and small group meetings. For more information please visit: <http://lscwarsaw.com>.

Leonard Osser, CEO of Milestone Medical commented, "We are honored to present at this important international conference. We believe our participation in this event will further build awareness of our company within Polish and European financial markets. We look forward to discussing our technology innovations, future opportunities and progress in launching our new medical instruments in both the Europe and the U.S."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval in the U.S. and has recently received CE approval for both instruments in the European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.